A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
第3相
実施中（募集終了）
NCT03451851
| 対象疾患 | Psoriasis |
|---|
| 相 | 第3相 |
|---|
| スポンサー | Janssen Research & Development, LLC |
|---|
| ステータス | 実施中（募集終了） |
|---|
| 参加者数 | 120 名 |
|---|
| 介入（薬剤） | Guselkumab, Placebo for guselkumab, Etanercept |
|---|
| 開始日 | 2018年7月11日 |
|---|
| 完了日 | 2023年7月19日 |
|---|
| 結果公開日 | 2025年3月28日 |
|---|
概要
The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.
Part 1: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16
At Week 16 · Percentages of participants
| Group 1 (Part 1): Placebo (Week 0-16) | 16.0 Percentages of participants |
|---|
| Group 2 (Part 1): Guselkumab (Week 0-16) | 65.9 Percentages of participants |
|---|
| Group 3 (Part 1): Etanercept (Week 0-16) | 69.2 Percentages of participants |
|---|
| p-value | <0.001 |
|---|
| Difference in percentage | 49.9 (95% CI 25.9–69.4) |
|---|
Part 1: Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16
At Week 16 · Percentage of Participants
| Group 1 (Part 1): Placebo (Week 0-16) | 20.0 Percentage of Participants |
|---|
| Group 2 (Part 1): Guselkumab (Week 0-16) | 75.6 Percentage of Participants |
|---|
| Group 3 (Part 1): Etanercept (Week 0-16) | 69.2 Percentage of Participants |
|---|
| p-value | <0.001 |
|---|
| Difference in percentage | 55.6 (95% CI 32.1–74.0) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。